Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers

A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of a Single Oral Dose of VIMOVO (250 mg Naproxen/20 mg Esomeprazole)in Healthy Adult Subjects

This is an assessment of Pharmacokinetics of a single oral dose of VIMOVO in healthy adult volunteers.

A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of a Single Oral Dose of VIMOVO (250 mg Naproxen/20 mg Esomeprazole)in Healthy Adult Subjects

Inclusion Criteria:

• Healthy male and female subjects aged 18 to 55 years
• Capable of understanding and complying with the Clinical Study Protocol
• Body mass index (BMI) of 19 to 30 kg/m2 and weight of 50 to 100 kg

Exclusion Criteria:

• Previous enrollment in the present study
• Receipt of another investigational product within 4 weeks before this study or plans to participate in another study at the same time as this study
• Female subjects with a positive urine pregnancy test